Epygenix Therapeutics to Participate in RW Baird's Biotech Discovery Series
PARAMUS, N.J., July 21, 2022 (Newswire.com) - Epygenix Therapeutics, a clinical-stage biopharmaceutical company powered by a novel genetic screening platform focused on developing treatments for rare and intractable genetic epilepsies, today announced that Darren Cline, President and Chief Executive Officer, and Lorianne Masuoka, M.D., Chief Medical Officer, will participate in a fireside chat at RW Baird's Biotech Discovery Series. The 45-minute fireside chat is scheduled to be held on Tuesday, July 26, 2022, at 1:30 p.m. ET.
To register for the live webcast, please contact your RW Baird representative. A replay of the webcast will be available through RW Baird for a limited time following the event.
About Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing drugs to treat rare and intractable forms of genetic epilepsy in childhood, such as Dravet Syndrome. Epygenix is currently focused on developing EPX-100, EPX-200, and EPX-300. These drug candidates reduce convulsive behavior and electrographic seizure activity and were discovered in a zebrafish Dravet Syndrome model which replicates the genetic mutation and mimics the human pathology.
Epygenix's largest shareholder is Mstone Partners, an entrepreneurial biotech incubator in the form of a holding company which owns and manages a portfolio of drug development companies. Mstone focuses on developing novel and repurposed drugs for rare, neurodegenerative disorders. Since 2016, Mstone has invested in two companies in the U.S. and one in Hong Kong which are now in advanced clinical stages with U.S. FDA. Mstone has also established a number of portfolio companies under the Curestone Platform, which manages a portfolio of drug development companies in a centralized, hub-and-spoke model.
For more information, please visit www.epygenix.com.
Head of Investor Relations and Business Development Director
Source: Epygenix Therapeutics